<DOC>
	<DOCNO>NCT01125774</DOCNO>
	<brief_summary>This multicenter study test hypothesis telcagepant superior placebo prevent perimenstrual migraine measure mean monthly headache entire treatment period . This study also evaluate safety tolerability telcagepant female migraine participant .</brief_summary>
	<brief_title>Telcagepant Prevention Menstrually Related Migraine Female Participants With Episodic Migraine ( MK-0974-065 )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Participant regular menstrual cycle monthly ( 22 32 day ) least last 3 cycle Participant experience headache menstrual period least 2 last 3 cycle Participant history migraine ≥ 3 month ≥ 2 migraine attack per month 2 month prior screen Participant agree use effective method birth control duration study Participant basilar hemiplegic migraine headache Participant take medication acute headache 15 day per month 3 month prior screen Participant take prophylactic medication migraine daily dose change within 4 week prior screen Participant history significant liver disease Participant cardiac surgery symptom within 3 month screen Participant confound pain syndrome , psychiatric condition , dementia , major neurological disorder migraine Participant history neoplastic disease ≤ 5 year prior sign inform consent Participant history gastric small intestinal surgery Participant consume 3 alcoholic drink per day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Menstrually relate migraine</keyword>
	<keyword>migraine</keyword>
	<keyword>Premenstrual migraine</keyword>
</DOC>